Cervical Cancer
If it’s your first time on this website, please read the disclaimer section.
Jun 15 – Jun 22, 2026
Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.
NAT REV CLIN ONCOL · Q1 JOURNAL - RANK #2/326TOP-TIER
This review provides an overview of antibody-drug conjugates (ADCs) in gynaecological malignancies, detailing key advances and future opportunities. It highlights three ADCs currently approved for previously treated gynaecological cancers: mirvetuximab soravtansine for folate receptor-α-positive ovarian cancer, trastuzumab deruxtecan for HER2-expressing (3+ IHC) solid tumours, and tisotumab vedotin for cervical cancer. The abstract discusses current research priorities including novel targets, resistance mechanisms, sequencing strategies, toxicity management, and rational combinations, such as ADCs with immune checkpoint inhibitors. This offers clinicians a comprehensive update on ADC applications in gynaecological cancers, directly aligning with an interest in cancer-focused research and informing practical treatment considerations.
10.1038/s41571-026-01164-9
Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This population-based study investigated cervical cancer mortality trends and estimated reductions in young women in England following HPV vaccination, utilizing mortality data from 2001-2024 and Poisson regression. Key findings show a 100% mortality reduction in women aged 20-24 years with high vaccination coverage (0 deaths vs. 23.1 expected). Overall, HPV vaccination was associated with a reduction of approximately 199.6 cervical cancer deaths (95% CI 125.0-274.2) by 2024, providing robust evidence for cancer prevention. These results strongly support global cervical cancer elimination goals and underscore the critical need for high vaccine uptake among young adolescents.
10.1016/S0140-6736(26)00918-9
May 04 – May 11, 2026
Substantial increases in cervical cancer inequalities worldwide without enhanced human papillomavirus vaccination and screening efforts: a global modelling study.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This global mathematical modelling study used the HPV-ADVISE model to project cervical cancer incidence and inequalities in 67 low-income and 42 high-income countries under various HPV vaccination and screening scenarios. Findings indicate that under current strategies, LMIC incidence would decrease by only 23%, while HICs achieve elimination by 2048, leading to a substantial increase in inequalities (RR=3 in 2022 to 12 in 2105). Reaching 90% girls’ vaccination in LMICs would reduce inequalities (RR=2 in 2105) and achieve elimination outside sub-Saharan Africa. Enhanced prevention strategies, including WHO targets and universal vaccination, are crucial for cervical cancer elimination in LMICs and attenuating global disparities.
10.1016/S0140-6736(26)00410-1